Scientific Program

Monday, 27 November


 08:00-17:15

 Registration 

08:50-09.00

 Congress Opening

09:00-10:30

 Session I: Opening and Keynote Presentations
   09:00-09:25  
 Lessons from High Impact Clinical Trials in 2017
 Ralph DeFronzo, USA
 
 09:25-09:50
 Innovation in Diabetes – What’s Ahead

 Francesco Giorgino, Italy 



 09:50-10:15
 Changing Management Guidelines: Good  Evidence and Bad Evidence
 Philip Home, UK

 10:15-10:30
 Discussion

10:30-11:00

 Networking Break and visit the Exhibition

11:00-12:30

 Session II: Current Regulatory Trends in Diabetes and Drug Development

   11:00-11:20 
 EMA Perspective
 Giuseppe Rosano, UK

 11:20-11:40 
 US and FDA Perspective 
 Zan Fleming, USA

 11:40-12:00 
 How to Pick and Qualify a CRO
 James Nolan, Inclinica, USA

 12:00-12:20
 Asia/China Perspective
 Guang Ning, China

 12:20-12:30
 Discussion 

 12:30-13:30

 Lunch Break, Networking and visit the Exhibition

 13:30-15:00

 Session III: Design a Clinical Program for Success
   13:30-13:45 
 Convincing Authorities for Innovative Endpoints 
 Zan Fleming, USA

 13:45-14:00
 How New Technologies may Help in Designing Trials in Diabetes
 Paolo Pozzilli, Italy

 14:00-14:15
 The Role of DSMB (IDMC)
 Philip Home, UK

 14:15-14:30
 Clinical Trials in Emerging Nations
 Guang Ning, China

 14:30-14:45 
 Assessing and Measuring Hypoglycemia 
 Avivit Cahn, Israel

 14:45-15:00 
 Clinical Trials in Older Patients with Frailty Syndrome a Need for Evidence Based  Studies
 Markolf Hanefeld, Germany

 15:00-15:30

 Networking Break and visit the Exhibition

 15:30-17:00

 Session IV:  Oral Presentations from Selected Abstracts

 

15:30-15:40
Pregnancy Outcomes: Effects of Metformin (POEM) Study in Gestational Diabetes Mellitus - a Long Term Randomized Controlled Trial
Adriaan Kooy
, The Netherlands

15:40-15:50
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in type 2 diabetes
Emilie Hein Zobel
, Denmark

15:50-16:00
Hypomagnesaemia in Diabetes patients: Comparison of Serum to Intracellular Measurement of Responses to Magnesium Supplementation and its role in Inflammation
Nadia Zghoul
, Kuwait

16:00-16:10
Improvement of type 2 diabetes (T2DM) in 250 hypogonadal men with testosterone therapy for 8 years: real-life registry data
Farid Saad
, Germany

16:10-16:20
Zygosids - the Novel Family of Complexes for Treatment and Prevention of Type 2 Diabetes
Mordechai (Mottie) Chevion, Vladimir Vinokur, Dror Chevion, Israel

Additional orals will be added

 17:00

 Networking Reception in the Exhibition Area


Tuesday, 28 November

 08:30-17:00

 Registration 

 09:00-10:30

 Session V: Phase 2/3 Studies
   09:00-09:20
 Why are Phase 2 Studies so Often Misleading?
 Andreas Pfützner, Germany

 09:20-09:40
 Diabetic Neuropathy and / or  Tools to Quantify Vascular Effects in Phase Studies  and / or Biomarkers in Diabetes Studies
 Thomas Forst, Profil, Germany

 09:40-10:00 
 Public Perception of Clinical Trials for Diabetes
 Helen Gao, Close Concerns, USA

 10:00-10:20
  Can Real World Evidence Substitute for RCTs to Gain Approval for New Drugs?
  Eberhard Standl, Germany

 10:20-10:30 
 Discussion

 10:30-11:45

Coffee Break, Exhibition and  Guided Poster Walks and visit the Exhibition

11:45-12:45

 Session VI: Cardiovascular Outcome Studies Part 1: What can we Learn from    Retrospective Data
   11:45-12:15 
 Merits of Observational versus Randomized Clinical Trial Data
 John Lachin, U.S.A

 12:15-12:35 
 Big Data: Advantages and Shortfalls
 Ran Goshen, Israel

 12:35-12:45 
 Discussion

 12:45-13:45

Lunch Break, Networking and visit the Exhibition

 13:45-15:30

 Session VII: Cardiovascular Outcome Studies Part 2: Design, Interpretation and Translation
   13:45-14:15 
 Next Generation of Diabetes Trials (Round Table)
 Neda  Rasouli, USA, Ralph DeFronzo, USA, Zan Fleming, USA

 14:15-14:30 
 Considerations in the Selection and Analysis of Multiple Outcomes
 John Lachin, USA

 14:30-14:45
 Algorithm Dilemma for the Management of Diabetes.
 Antonio Ceriello, Spain

 14:45-15:00
 Clinical Trials in Diabetic Kidney Disease: The Need for a Personalized Approach 
 Hiddo J. Lambers Heerspink, Netherlands 
 15:00-15:15
 Interpretation and Translation of Cardiovascular studies in clinical  practice
 Neda  Rasouli, USA

 
15:15-15:30
 CVOTs 2017 - what have we learned?
 Oliver Schnell,  Germany

 15:30-16:00

 Networking Break and visit the Exhibition

16:00-17:00

 Session VIII: Special National Program to Enhance Drug Development
   16:00-16:30
 Special National Program to Enhance Drug Development 

 16:30-16:45
  The Importance of IP and How to Select the Right Lawyer and Firm
  James Nolan, InClinica, USA
 
 16:45-17:00
 Panel Discussion

17:00

 Congress Closing